Immediate Impact
35 standout
Citing Papers
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023)
2024 Standout
Works of Zachary A. Hing being referenced
Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia
2015
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Zachary A. Hing | 58 | 30 | 40 | 46 | 5 | 99 | |
| Yufu Lin | 49 | 27 | 16 | 34 | 7 | 76 | |
| M Asuncion Echeveste | 60 | 16 | 12 | 46 | 4 | 73 | |
| Zlatana Pasalic | 67 | 44 | 92 | 36 | 6 | 167 | |
| Anouk de Jong | 96 | 25 | 28 | 64 | 7 | 111 | |
| Iryna Kriachok | 79 | 28 | 16 | 64 | 8 | 85 | |
| Betty Prine | 50 | 14 | 33 | 40 | 6 | 109 | |
| Johan A. Dobber | 92 | 50 | 13 | 50 | 7 | 122 | |
| Frédéric Davi | 37 | 51 | 41 | 58 | 6 | 177 | |
| Lawrence J. Prograis | 165 | 34 | 20 | 46 | 4 | 184 | |
| André Bortolini Silveira | 24 | 25 | 66 | 14 | 5 | 117 |
All Works
Loading papers...